Amphastar Pharmaceuticals stock
AMPHNASDAQAmphastar Pharmaceuticals, Inc., HealthcareISIN US03209R1032
76Score 76 out of 100, Strong
Price and trend
86 / 100
Price history
+3.7% in one yearThe chart shows daily closes over 12 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 29% above it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 75).
The price is 1.8% below its 52-week high. Largest decline in 12 years: 74% (August 2023 to May 2026).
Chart figures for advanced users
- SMA 50$25.84
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$22.34
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)75
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$16.87
- The lowest closing price of the last twelve months.
- Resistance$29.40
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Amphastar Pharmaceuticals, Inc. belongs to the Drug Manufacturers (Specialty & Generic) industry (United States) and, with a market value of $1.23B, is number 64 of 78 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $719.89M (down 1.7% year on year) and earnings of $98.09M (down 38.5%).
- For fiscal 2026, analysts expect on average revenue of $747.32M (up 3.8%) and adjusted earnings per share of $2.96 (down 8.9%).
Show more
- MEQIRI Score 76 out of 100 (Strong): rank 50 of 714 in Healthcare, median 53.
- The P/E is 12.7 (Drug Manufacturers (Specialty & Generic) median 19.3, own median of recent years 18.2).
- Our model puts fair value at $36.87, with the price 22% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 134.2% a year since 2020.Growth 94
- Growing faster than its industryRevenue up 15.5% a year since 2020, Drug Manufacturers (Specialty & Generic) median 8.7%.Growth 94
- Modestly valuedP/E 12.7, Drug Manufacturers (Specialty & Generic) median 19.3, own median 18.2.Valuation 68
Weaknesses
- Volatile share priceVolatility 51% a year over the last 12 months.Stability 63
Its standout strengths are growth and technical analysis.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
What lowers it
- price near its 52-week high
- solid fundamentals
Valuation
Valuation signal
Modestly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $26.33 and expensive above $61.45 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $29.61 (cash-flow model) and $44.12 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $34.57, at 7.8% it would be $40.31.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 3.1% on the twelve months before. Revenue has grown strongly since 2011, at around 14% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 49%, operating 20%, net 14%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 5 Nov 2026EPS reported $1.14 (expected $0.86)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $2.96−0.3%
- Revenue
- $747.32M−0.1%
- Earnings per share
- $3.17−0.3%
- Revenue
- $783.99M−0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +2.7%Overall sales guidance of mid to high single digit growth maintained; remediation at the IMS facility adds $2 to $3 million of expense per quarter and slightly slows IMS sales.
“Due to remediation efforts at our IMS facility, we expect expenses there will increase by $2 million to $3 million per quarter for the next several quarters.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $1.58M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Peters William JSale
5 Nov 2026, CFO, EVP & TREASURER
- Shares
- 12,631
- Price
- $28.99
- Value
- $366,189
- Peters William JSale
4 Nov 2026, CFO, EVP & TREASURER
- Shares
- 16,000
- Price
- $28.03
- Value
- $448,480
- Peters William JSale
21 Sept 2026, CFO, EVP & TREASURER
- Shares
- 4,139
- Price
- $25.00
- Value
- $103,475
Show 4 more
- Zhou RongSale
16 Sept 2026, SENIOR EVP, PRODUCTION CENTER
- Shares
- 10,000
- Price
- $23.94
- Value
- $239,404
- Zhou RongSale
2 Sept 2026, SENIOR EVP, PRODUCTION CENTER
- Shares
- 3,187
- Price
- $23.63
- Value
- $75,306
- Prins Richard KSale
11 Aug 2026, Board
- Shares
- 7,973
- Price
- $20.30
- Value
- $161,852
- Peters William JSale
7 Aug 2026, CFO, EVP & TREASURER
- Shares
- 8,180
- Price
- $22.48
- Value
- $183,886
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Amphastar Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 76
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Pacira BioSciencesPCRX $1.46B58
- Phibro Animal HealthPAHC $1.43B58
- Cronos GroupCRON $1.26B61
- BioGaiaBIOG-B.ST $1.25B75
- VetoquinolVETO.PA $1.13B77
- Harrow HealthHROW $1.1B39
- PharmanutraPHN.MI $906.68M62
- Ironwood PharmaceuticalsIRWD $806.23M71
ETFs that hold Amphastar Pharmaceuticals
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.08% | 0.35% | €1.21B |
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.07% | 0.39% | €1.47B |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.05% | 0.30% | €2.28B |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.04% | 0.30% | €185.82M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.03% | 0.30% | €944.34M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.17B |
| Invesco Global Buyback Achievers UCITS ETFBBCK | 0.01% | 0.39% | €188.08M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 4 Sep 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.